Can-Fite BioPharma Ltd.
CANF
$1.23
-$0.03-2.38%
AMEX
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 179.00K | 179.00K | 158.00K | 158.00K | 155.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 179.00K | 179.00K | 158.00K | 158.00K | 155.00K |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 179.00K | 179.00K | 158.00K | 158.00K | 155.00K |
| SG&A Expenses | 761.00K | 761.00K | 762.50K | 762.50K | 722.00K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 2.20M | 2.20M | 2.21M | 2.21M | 1.99M |
| Operating Income | -2.02M | -2.02M | -2.05M | -2.05M | -1.83M |
| Income Before Tax | -1.96M | -1.96M | -1.98M | -1.98M | -1.65M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -1.96M | -1.96M | -1.98M | -1.98M | -1.65M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1.96M | -1.96M | -1.98M | -1.98M | -1.65M |
| EBIT | -2.02M | -2.02M | -2.05M | -2.05M | -1.83M |
| EBITDA | -2.02M | -2.02M | -2.05M | -2.05M | -1.83M |
| EPS Basic | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Normalized Basic EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Normalized Diluted EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average Basic Shares Outstanding | 2.53B | 2.53B | 1.82B | 1.82B | 1.48B |
| Average Diluted Shares Outstanding | 2.53B | 2.53B | 1.82B | 1.82B | 1.48B |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |